Latest News and Press Releases

Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf

EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance...

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases

Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...

In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.

Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).

Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.